We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Microarray Immunoassay Identifies Patients with Peanut Allergy

By LabMedica International staff writers
Posted on 28 May 2012
An allergy diagnostic method has been developed that could correctly predict symptomatic peanut allergy by using peptide microarray immunoassays and bioinformatic methods.

Peanut allergy is relatively common, typically permanent, and often severe and a laboratory test that could accurately diagnose symptomatic peanut allergy would greatly facilitate clinical practice. More...


Scientists at the Mount Sinai School of Medicine, (New York, NY, USA) recruited selectively 62 children and adolescents from a larger group of referred patients for the evaluation of peanut allergy between 2001 and 2007. Of the 62 patients, 31 had symptomatic peanut allergy and 31 had outgrown their peanut allergy or were sensitized, but were clinically tolerant to peanut.

A peptide microarray immunoassay was used to compare immunoglobulin E (IgE) and IgG4 binding to the peptides of three major peanut allergens between those with symptomatic peanut allergy and those who had outgrown their allergy or were sensitized but clinically tolerant to peanut ingestion. Specific IgE and IgG4 binding to 419 overlapping peptides covering the amino acid sequences of Arachis hypogaea (Ara h) allergens Ara h 1, Ara h 2, and Ara h 3 were measured by using a peptide microarray immunoassay. Bioinformatic methods were applied for data analysis. The library of overlapping peptides was printed in two sets of duplicates onto Arrayit SuperEpoxy glass slides (Arrayit Corporation, Sunnyvale, CA, USA).

The patients who had symptomatic peanut allergy showed significantly greater IgE binding and broader epitope diversity than did peanut-tolerant individuals. No significant difference in IgG4 binding was found between groups. By using machine-learning methods, four peptide biomarkers were identified and prediction models that can predict the outcome of double blind, placebo-controlled food challenges with high accuracy were developed by using a combination of the biomarkers.

The authors concluded that the novel diagnostic approach could predict peanut allergy with high accuracy by combining the results of a peptide microarray immunoassay and bioinformatic methods. However, they note that further studies are needed to validate the efficacy of this assay in clinical practice. The study was published on in the May 2012 issue of the Journal of Allergy and Clinical Immunology.

Related Links:
Arrayit Corporation
Mount Sinai School of Medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.